Tuesday, 17 March 2009

Med BioGene Appoints New CFO

Basic shares: 40 million
Fully diluted: 58 million

In a news release issued on March 16, 2008, Med BioGene announced the addition of Canadian life science industry veteran, David Matthews as Chief Financial Officer.

Med BioGene will be leaning on Mr. Matthews’ experience as the company gears up to commercialize LungExpressDx™, a proprietary gene expression-based assay for early-stage lung cancer that will be used to determine patients who will benefit from chemotherapy. Management expects a full launch to occur during the second half of 2009.

David Matthews’ brings MBI impressive experience, spanning over 20 years in the life sciences industry. Former positions include: Managing Director of Aspreva Pharmaceuticals SA, the European subsidiary of Aspreva Pharmaceuticals, CFO of StressGen Biotechnologies and CFO of Allelix Biopharmaceuticals. Mr. Matthews received his MBA (Finance) at Clarkson University.